- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
American Academy of Neurology and International League against Epilepsy release guidelines for the use of antiepileptic drugs in patients with HIV/AIDS
Clinicians are urged to be cautious when selecting an antiepileptic drug (aeD) for patients with HIV/AIDS, according to new evidence-based guidelines developed by the American Academy of Neurology (AAN) and the International League Against Epilepsy (ILae).
Clinicians are urged to be cautious when selecting an antiepileptic drug (AED) for patients with HIV/AIDS, according to new evidence-based guidelines developed by the American Academy of Neurology (AAN) and the International League Against Epilepsy (ILAE).
According to AAN and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the ILAE, seizure disorders are common in HIV-infected or AIDS individuals, with incidence rates reported to be as high as 11% in this population.
Seizures in HIV/AIDS patients are often due to presence of opportunistic infections of the central nervous system and may require AED treatment. In addition, AEDs are being used more frequently for non-seizure indications (ie, peripheral neuropathies, psychiatric disorders). For these reasons, the 2 organizations believe "worldwide the concurrent use of AEDs and antiretroviral drugs (ARV) is substantial;" with AED coadministration occurring in more than half of the individuals taking ARVs.
Through a systematic review of the literature, the guideline committee found cohort and pharmacokinetic studies indicating that enzyme-inducing (EI) AEDs interact with ARVs, albeit, few studies evaluated drug interactions between newer ARV agents and AEDs. Upon review of this literature, the AAN and ILAE are now recommending the following:
The authors of the guidelines also emphasized, "The optimal choice of epilepsy treatment in patients with HIV should reflect an accounting for the metabolic and inhibitory/inducing profiles of coadministered drugs."
The guidelines concluded by encouraging clinicians who prescribe ARVs and AEDs to consult the US Department of Health and Human Services treatment guidelines for HIV/AIDS, which provide specific recommendations for the management of possible drug-drug interactions with AED-ARV combinations.
SOURCES
Birbeck GL, French JA, Perucca E, Simpson DM, et al. Evidence-based guideline: Antiepileptic drug selection for people with HIV/AIDS Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against Epilepsy. Neurology. 2012;78:139–145.
Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. October 14, 2011; 1–167. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed December 31, 2011.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.
